News

Filter

Current filters:

None

7884 to 7893 of 96126 results

Biogen Idec files oral MS candidate in USA

01-03-2012

US biotech firm Biogen Idec (Nadaq: BIIB) has submitted its orally-active drug for relapsing-remitting…

Biogen IdecBiotechnologyNeurologicalRegulation

Genzyme to start shipping Fabrazyme from newly-approved plant

01-03-2012

French drug major Sanofi's (Euronext: SAN) US subsidiary Genzyme says that it has begun shipping its…

BiotechnologyFabrazymeGenzymeMarkets & MarketingPharmaceuticalRare diseasesSanofi

German pharma hails progress against cancer and rare diseases

01-03-2012

Never has the pharmaceutical industry made as much progress against cancer as in the past few years,…

EuropeOncologyPharmaceuticalResearch

Unmet needs in nasopharyngeal cancer therapeutics continue to frustrate clinicians

01-03-2012

Clinicians treating patients with nasopharyngeal cancer may have to wait for the scientific breakthrough…

Markets & MarketingOncologyPharmaceuticalResearch

EMA increases public information on conflicts of interest of experts and management

01-03-2012

The European Medicines Agency this week updated its list of European experts to display each expert's…

EuropeManagementPharmaceuticalRegulation

Hi-Tech and Mylan update on generics

01-03-2012

US generic drugmaker Hi-Tech Pharmacal (Nasdaq: HITK) says that the US Food and Drug Administration has…

GenericsMarkets & MarketingNeurologicalNorth AmericaRegulation

Avanir and Concert Pharma link up for nervous system disorders

01-03-2012

USA-based companies Avanir Pharmaceuticals (Nasdaq: AVNR) and Concert Pharmaceuticals have entered into…

LicensingNeurologicalPharmaceutical

Shire buys rights to arGEN-X technology for rare diseases

01-03-2012

Dutch/Belgian preclinical stage biotech company arGEN-X, focused on the discovery and development of…

BiotechnologyLicensingPharmaceuticalRare diseases

7884 to 7893 of 96126 results

Back to top